ArcherDX Announces Tumor Panels Launch
ArcherDX announced on Thursday the global launch of its FusionPlex lung thyroid and FusionPlex solid tumor panels, next-generation sequencing assays that detect gene translocations in clinical samples.
The lung thyroid panel detects and classifies fusions of eight genes linked with non-small cell lung and thyroid cancers while the solid tumor panel boasts the devicemaker’s largest catalog gene panel, able to detect and classify fusions and other mutations associated with more than 50 different genes, the company says.
The assays are the most comprehensive fusion assays on the market, a spokesman told Device Daily Friday.
The company plans DNA and complementary RNA fusion assays launches throughout the year. The devicemaker’s kits have been designated for research use only.
ArcherDX is based in Boulder, Colo., with manufacturing operations in Beverly, Mass. — Jason Scott